

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102777 A2

(51) International Patent Classification⁷: **C07D 211/22**

(21) International Application Number: **PCT/US01/23994**

(22) International Filing Date: **31 July 2001 (31.07.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
484/MAS/2001 **18 June 2001 (18.06.2001)** **IN**

(71) Applicant (for all designated States except GD, US): **DR. REDDY'S LABORATORIES LTD.** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).

(71) Applicant (for GD only): **CORD, Janet, I.** [US/US]; 26 West 61st Street, New York, NY 10023 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REDDY, M., Satyanarayana** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500

016, A.P. (IN). **RAJAN, S., Thirumalai** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN). **RAO, U., V., Bhaskara** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).


(74) Agent: **CORD, Janet, I.**; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-\$G(A)\$, \$G(A)\$-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE**



(57) Abstract: The present invention is related to novel polymorph of Fexofenadine and Fexofenadine hydrochloride of formula 1 and process of preparation thereof. The present invention is also directed to provide pure novel polymorphs of Fexofenadine and its hydrochloride by a simple process which is cost effective, commercially viable and environment friendly.



Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1. -


NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL]-1-HYDROXYBUTYL]- α,α -DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE

Field Of The Invention

5 The present invention relates to a novel crystalline form of fexofenadine hydrochloride and to a process for the preparation thereof. More specifically, the present invention relates to a novel anhydrous crystalline Form X of fexofenadine hydrochloride. The present invention also relates to a novel crystalline form of fexofenadine, particularly Form A of fexofenadine and to a process for the preparation thereof.

Background Of Invention

10 Chemically fexofenadine hydrochloride is 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α,α -dimethylbenzene acetic acid hydrochloride. It is also known as terfenadine carboxylic acid metabolite. It is represented by Formula 1.



Formula 1

15 Fexofenadine hydrochloride is useful as an antihistamine, and does not cause the adverse effects associated with the administration of terfenadine including abnormal heart rhythms in some patients with liver disease or patients who also take the antifungal drug ketoconazole or the antibiotic erythromycin.

20 U.S. Patent No. 4,254,129 ("the '129 patent") entitled Piperidine Derivatives issued on March 3, 1981. The '129 patent relates to substituted piperidine derivatives and methods of making and using them. The disclosed compounds, including fexofenadine and its pharmaceutically acceptable salts and individual optical isomers, are purported to be useful as antihistamines, antiallergy agents and bronchodilators.

25 The '129 patent discloses a process for the preparation of fexofenadine having a melting point of 195-197°C. The recrystallization process exemplified therein in Example 3, column 13, involves use of a mixture of solvents for preparation of fexofenadine.

- 2 -

WO 95/31437 discloses processes for preparing hydrated and anhydrous forms of piperidine derivatives, polymorphs and pseudomorphs thereof, which are useful as antihistamines, antiallergic agents and bronchodilators.

WO 95/31437 discloses the preparation of anhydrous forms of fexofenadine hydrochloride by subjecting the hydrated fexofenadine hydrochloride to an azeotropic distillation or to water minimizing recrystallization. In the invention described in this application, unlike the process described in WO95/31437, hydrated Fexofenadine Hydrochloride is not converted to anhydrous Fexofenadine Hydrochloride, but instead Fexofenadine is converted to Form A of Fexofenadine and then to anhydrous Form X of Fexofenadine Hydrochloride. The novel anhydrous crystalline form of Fexofenadine Hydrochloride is obtained according to the present invention directly from the novel precursor i.e. Fexofenadine without generating a hydrated form. The starting material used Fexofenadine (Base) is different than described in WO 95/31437.

WO 00/71124A1 discloses amorphous fexofenadine hydrochloride process, its preparation and a composition containing it.

Fexofenadine obtained in the prior art processes, is a mixture of regioisomers of fexofenadine containing 33% of para isomer and 67% of meta isomer. These components are referred to as inseparable and it is also stated that it is not possible to obtain either of the regioisomers in substantially pure form. On the other hand, Fexofenadine prepared according to the process of this invention has a purity of > 99.5%. In the novel crystalline Fexofenadine of this invention, the meta isomer of Fexofenadine is at a level of below 0.1%. Purity of fexofenadine is critical when it is used for the conversion to its hydrochloride salt since it is very difficult to remove any undesired impurities, including regioisomers, from the desired compound in last late processing stage. Removing the impurities increases the cost of production. Hence it is generally preferred that the HPLC purity of fexofenadine is greater than 99.5 %.

Another beneficial aspect of the present invention is that, the fexofenadine hydrochloride is obtained in almost quantitative yield from the precursor i.e. fexofenadine. Almost quantitative yield means that the pure fexofenadine is converted to fexofenadine hydrochloride quantitatively (> 92 % yield of theory), with almost no yield loss, as the fexofenadine base itself is >99.5 % pure as compared to fexofenadine prepared by the prior art processes.

- 3 -

Summary of the Invention

Therefore, an object of the present invention is to provide a novel crystalline form of fexofenadine and a process for its preparation.

Another object of the present invention is to provide a novel anhydrous
5 crystalline form of fexofenadine hydrochloride (Formula 1) and a process for its preparation, which can be obtained directly from fexofenadine without generating a hydrated form of fexofenadine hydrochloride.

A further object of the present invention is to provide pure novel polymorphs of fexofenadine and its hydrochloride by a simple process which is cost effective,
10 commercially viable and environmentally friendly.

Brief Description Of Accompanying Drawings

Fig.1 is a characteristic X-ray powder diffraction pattern of Form A of fexofenadine. Vertical axis: Intensity (CPS); Horizontal axis: Two Theta (degrees). The significant d values (\AA) obtained are 23.11, 11.50, 8.29, 7.03, 6.67, 6.16, 6.02, 5.75,
15 5.43, 5.33, 5.07, 4.69, 4.63, 4.44, 4.20, 4.15, 4.07, 3.55, and 3.44.

Fig.2 is a characteristic infrared absorption spectrum in potassium bromide of aforementioned Form A of fexofenadine. [Vertical axis, Transmission (%); Horizontal axis: Wave number (cm^{-1})]. The characteristic peaks for Form A are indicated at 3421, 3058, 2936, 2366, 2343, 1571, 1509, 1490, 1447, 1390, 1334, 1167, 1097, 1073, 1018,
20 960, 916, 849, 745, 706, 666, 637, 617, 541.

Fig.3 is a characteristic of differential scanning calorimetry thermogram of aforesaid Form A of Fexofenadine. Vertical axis: mW; Horizontal axis: Temperature ($^{\circ}\text{C}$). The DSC thermogram exhibits a melt endotherm at about 230.38°C .

Fig. 4 is a characteristic X-ray powder diffraction pattern of Form X of fexofenadine hydrochloride. Vertical axis: Intensity (CPS); Horizontal axis: Two Theta
25 (degrees). The significant d values (\AA) obtained are 16.05, 12.98, 8.29, 8.06, 6.25, 5.97, 5.54, 5.41, 4.89, 4.70, 4.55, 4.37, 4.32, 4.15, 4.03, 3.80, 3.67, 3.57, 3.42.

Fig.5 is a characteristic infrared absorption spectrum in potassium bromide of aforementioned Form X of Fexofenadine hydrochloride. [Vertical axis, Transmission (%);
30 Horizontal axis: Wave number (cm^{-1})]. The characteristic peaks for Form X are indicated at 3370, 2965, 2652, 1717, 1472, 1448, 1250, 1158, 1100, 1068, 995, 962, 840, 747, 703, 638, 560.

Fig.6 is a characteristic of differential scanning calorimetry thermogram of aforesaid Form X of Fexofenadine hydrochloride. Vertical axis: mW; Horizontal axis: Temperature (°C). The DSC thermogram exhibits a melt endotherm at about 186.56°C.

Detailed Description Of Invention

5 The present invention provides a novel crystalline form of Fexofenadine, which is designated as Form A for convenience. The process for the preparation of novel crystalline Form A, comprises recrystallization of crude fexofenadine in an alcohol followed by azeotropically refluxing Fexofenadine in a non polar organic solvent, organic solvent or a mixture thereof and the subsequent isolation of the desired Form A.

10 Form A is prepared by a process, which comprises:

- a. recrystallizing crude Fexofenadine in a (C₁-C₃)alkanol followed by;
- b. azeotropically refluxing Fexofenadine in a non polar organic solvent, an organic solvent or a mixture thereof for 15 minutes to 6 hours, preferably 1-3 hours;
- c. stirring the reaction mixture at ambient temperature for 30 minutes to 2 hours;

15 and

- d. isolating the Form A of Fexofenadine by conventional methods.

Crude fexofenadine can be recrystallized in methanol, ethanol or isopropanol, preferably methanol. The ratio of crude Fexofenadine to the (C₁-C₃) alkanol is 1:10-20. The ratio of fexofenadine to nonpolar organic solvent and/or organic solvent in step b) is

20 1:10-15.

The non polar organic solvents referred to herein are selected from xylene or toluene or a (C₆-C₉) alkyl such as n-hexane, hexane, heptane, octane, nonane or cyclohexane. Toluene is the preferred non polar organic solvent. The organic solvents are (C₁ to C₄) alkyl acetates and are selected from methyl, ethyl, propyl, and butyl acetate,

25 preferably ethyl acetate.

The Form A of Fexofenadine can be identified by the following characteristics:

- a visual melting point (capillary tube) in the range of about 218-228°C;
 - a melting endotherm at about 227-231°C as determined by differential scanning calorimetry;
 - and an X-ray powder diffraction pattern essentially as shown in the Table 1.
- 30

- 5 -

Table 1

D-Space, Angstroms	Intensity, I/I ₀ , %
d value	I / I ₀
23.11	51
11.50	44
8.29	79
7.03	28
6.67	48
6.16	50
6.02	24
5.75	23
5.43	75
5.33	52
5.07	100
4.69	27
4.63	32
4.44	66
4.20	52
4.15	55
4.07	38
3.55	21
3.44	20

According to another aspect, the present invention provides a process for preparing a novel crystalline form of Fexofenadine Hydrochloride, designated as Form X.

The process for the preparation of novel crystalline Form X of fexofenadine hydrochloride, comprises reaction of fexofenadine Form A in non polar solvent, with a suitable solvent containing hydrogen chloride and isolating the desired Form X of fexofenadine hydrochloride which can be obtained directly from fexofenadine without generating a hydrated form of fexofenadine hydrochloride.

The Form X polymorph is prepared by a process, which comprises:

- a. recrystallizing crude Fexofenadine in (C₁-C₃) alkanol followed by;
- b. azeotropically refluxing Fexofenadine in a non polar organic solvent, an organic solvent or mixtures thereof for 15 minutes to 6 hours, preferably 1-3 hours;
- c. stirring the reaction mixture at ambient temperature for 30 min to 2 hours;
- d. optionally isolating the Fexofenadine Form A by conventional methods ;
- e. if isolated, suspending Fexofenadine Form A, in a non polar organic solvent;
- f. adjusting the pH of the reaction mass to 1 to 3, preferably 2 with a suitable solvent containing hydrogen chloride;

- 6 -

- g. stirring the reaction mass for 30 minutes to 18 hours, preferably 1-10 hours and more preferably 3-6 hours at ambient temperature;
- h. filtering the solid obtained followed by drying at 60-100°C;
- i. suspending the solid obtained in step (h) in an alkyl acetate and heating the
5 reaction mixture to reflux for 0.5 -6 hours preferably 1-3 hours;
- j. stirring the reaction mixture at ambient temperature for 20 minutes to 2 hours; and
- k. isolating the anhydrous crystalline Form X of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α - dimethylbenzene acetic
10 acid hydrochloride, by conventional methods.

The preparation of Form X can be accomplished without isolation of Form A. The preparation of Form X can proceed directly from step (c) to step (f) eliminating steps (d) and (e).

- In variation of above process the preparation of novel Form X polymorph may be
15 accomplished by drying the solid obtained in step (h) at 110-160°C under reduced pressure for 30 minutes to 10 hours, preferably 2-5 hours.

The ratio of solid to alkyl acetate in step (i) is 1:10-15.

- Yet another aspect of the present invention is to provide a process for preparing a novel crystalline form of Fexofenadine Hydrochloride, designated as Form X, by seeding
20 technique.

This process comprises:

- a. recrystallizing crude Fexofenadine in a (C₁-C₃)alkanol followed by;
- b. azeotropically refluxing Fexofenadine in a non polar organic solvent for 3-4
hours;
- 25 c. optionally isolating the Fexofenadine Form A obtained in step b) by conventional methods accompanied by drying at below 100°C ;
- d. suspending the Fexofenadine Form A obtained in step c) or adding to the mixture of step b) a mixture of a nonpolar organic solvents selected from toluene or xylene or a (C₆-C₉)alkyl; or an organic solvent selected from (C₁-C₄) alkyl acetate
30 preferably ethyl acetate; and isopropanol, the ratio of solvent to isopropanol being 7-9:3-1 preferably 9:1 ;

- 7 -

e. adjusting the pH of the solution of step d) to 1 to 3 preferably 2 with a suitable solvent containing hydrogen chloride;

f. filtering the solution obtained in step e) to remove particulate matter;

g. seeding the solution of step f) with crystals of novel crystalline Form X and stirring the reaction mass at ambient temperature to separate the solid;

h. filtering the solid obtained in step g) followed by washing with a nonpolar organic solvent, organic solvent or hydrocarbon solvent; and

i. drying the anhydrous crystalline Form X of 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride at 70-100°C.

The crude fexofenadine may be recrystallized in a C₁-C₃ alkanol such as methanol, ethanol or isopropanol, preferably, methanol.

The non polar organic solvents referred to herein are selected from xylene or toluene or a (C₆-C₉) alkyl such as n-hexane, hexane, heptane, octane, nonane or cyclohexane. Mixtures of solvents may be used thereof. Toluene is the preferred solvent. The organic solvents are (C₁-C₄) alkyl acetates and are selected from methyl, ethyl, propyl and butyl acetate preferably ethyl acetate.

The suitable solvent containing hydrogen chloride referred to herein is selected from methanol, ethanol, isopropanol or t-butanol, preferably isopropanol.

The ratio of crude fexofenadine to the C₁-C₃ alkanol is 1:10-20. The ratio of fexofenadine to the solvents in step b. is 1:10-15.

The hydrocarbon solvent is selected from hexane or cyclohexane, preferably cyclohexane.

The Form X of Fexofenadine hydrochloride obtained by the processes described above can be identified by

- a visual melting point (capillary tube) in the range of about 180-188°C;
- a melting endotherm at about 180-189°C as determined by differential scanning calorimetry;
- and an X-ray powder diffraction pattern essentially as shown in the Table 2.

- 8 -

Table 2

D-Space, Angstroms	Intensity, I/I ₀ , %
d value	I / I ₀
16.05	78
12.98	65
8.29	62
8.06	27
6.25	46
5.97	29
5.54	100
5.41	38
4.89	69
4.70	97
4.55	92
4.37	23
4.32	33
4.15	22
4.03	58
3.80	43
3.67	34
3.57	33
3.42	35

The present invention provides a improved method for the preparation of Fexofenadine Form A in its pure form by a crystallization process which requires only a single solvent. This solvent may be recovered and reused, thereby rendering the process cost effective and environmentally friendly.

The novel polymorphic forms of fexofenadine of this invention may if desired be converted into one of its pharmaceutically acceptable salts.

It is noteworthy to mention that both Fexofenadine and its hydrochloride obtained by the present invention are pure and well suited for formulation. Most pharmaceuticals formulation processes are facilitated by use of the active materials that are free flowing high melting solids. The novel anhydrous crystalline Form A and X of Fexofenadine Hydrochloride of the present invention are a high melting solid, very suited for formulation.

Examples

The present invention is illustrated by the following examples, which are not intended to limit the effective scope of the claims.

- 9 -

Reference Example - for the Preparation of Fexofenadine Crude

To a solution of a mixture of methyl 4-[4-[4-(hydroxydiphenylmethyl)1-piperidinyl]-1-oxobutyl]- α,α -dimethylbenzeneacetate hydrochloride and methyl 3-[4-[4-(hydroxydiphenylmethyl)1-piperidinyl]-1-oxobutyl]- α,α -dimethylbenzeneacetate hydrochloride (100 g) in methanol (600 ml) is added aqueous sodium hydroxide (36.4 g sodium hydroxide in 132 ml of water). The mixture is heated to reflux for about 2-4 hours. Completion of the reaction is monitored by TLC method and upon completion the reaction mixture is cooled to ambient temperature accompanied by addition of sodium borohydride (6.8 g). The reaction mixture is heated to 50-60°C and maintained at the same temperature for about 14 hours (completion of the reaction is monitored by TLC method), and subsequently cooled to ambient temperature accompanied by carbon treatment. The clear filtrate obtained after carbon treatment, is stripped of methanol followed by addition of water (300 ml) and acetone (200 ml). The pH of the reaction mixture is then adjusted to ~6 with acetic acid, stirred for 5 hours and then filtered, followed by water wash (200 ml) to afford crude Fexofenadine.

Yield: 72 g

Example 1Preparation of Pure Fexofenadine

A solution of Fexofenadine crude (500 g; prepared as per reference example) in methanol (4000 ml) is refluxed for 1 hour and the reaction mixture is then cooled to room temperature. The precipitated pure Fexofenadine obtained was filtered and washed with methanol (250 ml). Repeated recrystallization in methanol afforded pure Fexofenadine of desired purity.

Purity by HPLC 99.85 %; Meta isomer < 0.1%

Example 2Step 1Preparation of Form A from Pure Fexofenadine

A suspension of pure Fexofenadine (180 g) in toluene (1800 ml) is azeotropically refluxed for 2 and a half hours. The reaction mixture is then cooled to room temperature and stirred for about 40 minutes. After completion of this step the reaction mixture was filtered and washed with toluene (180ml) and the obtained Form A of Fexofenadine is dried at 80-85°C under atmospheric pressure till constant weight.

- 10 -

Yield 179.2 g; M.R (melting range) 220-224°C.

Step 2

Preparation of Form X of Fexofenadine hydrochloride

To the Fexofenadine Form A (170 g; prepared as per procedure in step 1), toluene
5 (1700 ml) is added followed by slow addition of isopropanol hydrogen chloride (prepared
by purging hydrogen chloride to isopropyl alcohol) to pH 2. The reaction mass is then
stirred for 10 hours 15 minutes. The solid obtained is filtered, washed with toluene (170
ml) and dried under vacuum at 75-80°C. Solid thus obtained (140g) is refluxed in ethyl
acetate (2800ml) for about 1 hour. The reaction mixture is then cooled to room
10 temperature and stirred for 1 hour 30 minutes. The reaction mass is filtered and washed
with ethyl acetate (140ml). The desired Form X of Fexofenadine hydrochloride is
obtained after drying at 78-85°C under atmospheric pressure till constant weight.

Yield 129.6 g; M.R 183-187°C.

Example 3

Preparation of Form X of Fexofenadine hydrochloride

To the Fexofenadine Form A (95 g; prepared as per procedure under Example 2,
step 1), toluene (950 ml) is added followed by slow addition of isopropanol hydrogen
chloride (prepared by purging hydrogen chloride to isopropyl alcohol) to pH 2. The
reaction mass is then stirred for 2 hours 45 minutes. The reaction mass is filtered and
20 washed with toluene (95 ml) to isolate solid which is dried at 80-85°C under atmospheric
pressure till constant weight.

Part of the above-obtained solid was kept in oven to remove residual organic
solvents at 141-149°C at 100-mbar pressure, for 3 and half hours, to afford desired Form
X of Fexofenadine Hydrochloride M.R 183-188°C.

Example 4

Preparation of Form X of Fexofenadine hydrochloride

To pure Fexofenadine (50 g), toluene (500 ml) is added and the mixture is
refluxed azeotropically for about 3 hours. The reaction mass is then cooled to room
temperature followed by slow addition of isopropanol hydrogen chloride, to pH 2. The
30 reaction mass is then stirred for about 15 and a half hours. The separated solid is filtered,
washed with toluene (50 ml) and dried (Yield 43.3 g). Part of this solid (42g) is
suspended in ethyl acetate (420ml) and refluxed for about 1 hour (this operation was

- 11 -

performed for removal of residual organic solvents). The suspension is then cooled to room temperature and stirred for 20 minutes. The reaction mass is filtered and washed with ethyl acetate (42ml). The desired Form X of Fexofenadine hydrochloride is dried at 90-96°C to constant weight.

5 Yield 39 g: M.R 183-188°C.

Example 5

A suspension of pure Fexofenadine (prepared as per example 1; 100 g) in toluene (1000 ml) is azeotropically refluxed for 3-4 hours. The reaction mixture is then cooled to room temperature and stirred for about 15-30 minutes. Subsequently, the reaction
10 mixture is filtered and washed with toluene (100ml) and the Fexofenadine Form A obtained is dried below 100°C to constant weight.

Yield 95 g

To a mixture of ethyl acetate and isopropanol (900:100 ml), is added Fexofenadine Form A (100 g; prepared as per above procedure), followed by slow
15 addition of isopropanol hydrogen chloride (prepared by purging hydrogen chloride to isopropyl alcohol) to pH 2. The reaction mass is then filtered and to the filtrate is added several crystals of Form X of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride. The reaction mixture is then stirred for 2-4 hours. The solid obtained is filtered, washed with cyclohexane (200
20 ml) and dried below 100°C to constant weight to obtain the desired Form X of Fexofenadine Hydrochloride

Yield 100 g.

The aforementioned crystalline form X of Fexofenadine hydrochloride and Form A of Fexofenadine, in Examples 2-4 have been examined for their structural and
25 analytical data viz., Powder X-Ray Diffraction, Differential Scanning Calorimetry, and Infrared Absorption Spectroscopy.

The results obtained are discussed above and the respective drawings attached (Fig. 1-6).

The X-Ray Diffraction Pattern set out herein were obtained using Rigaku D /
30 Max-2200 X-Ray Powder Diffractometer having a Cu K- radiation source of wavelength $\lambda=1.54 \text{ \AA}$. The samples were scanned between 3-45 degrees 2θ .

- 12 -

The infrared absorption spectra were recorded in solid state as KBr dispersion on Perkin Elmer 1650 FT-IR spectrophotometer.

Differential Scanning Calorimetric analysis was performed on a Shimadzu DSC-50. The samples were heated to 250°C at a heating rate of 5°C / min with a 30ml/minute
5 nitrogen purge.

- 13 -

CLAIM

1. A crystalline Form A of 4-[4- [4-(hydroxydiphenylmethyl)—1- piperidinyl]—1-hydroxybutyl]- α , α - dimethylbenzene acetic acid (Form A of Fexofenadine) which is characterized by the following X-ray powder diffraction pattern (d values in \AA): 23.11,
5 11.50, 8.29, 7.03, 6.67, 6.16, 6.02, 5.75, 5.43, 5.33, 5.07, 4.69, 4.63, 4.44, 4.20, 4.15, 4.07, 3.55, and 3.44.
2. The crystalline Form A of Fexofenadine according to claim 1, characterized by the following infrared absorption peaks (in cm^{-1}) FT-IR (In KBr): 3421, 3058, 2936,
2366, 2343, 1571, 1509, 1490, 1447, 1390, 1334, 1167, 1097, 1073, 1018, 960, 916, 849,
10 745, 706, 666, 637, 617, 541.
3. The crystalline Form A of Fexofenadine according to claim 1, or 2, characterized by a melt endotherm with a peak temperature at about $227\pm 231^\circ\text{C}$.
4. A process for preparing Form A of 4-[4- [4- hydroxydiphenylmethyl] —1- piperidin-yl]- α , α - dimethylbenzene acetic acid (Form A of Fexofenadine) which
15 comprises:
 - a. recrystallizing crude Fexofenadine in a (C_1 - C_3) alkanol;
 - b. azeotropically refluxing Fexofenadine in a non polar organic solvent, an organic solvent or a mixture thereof for 15 minutes to 6 hours;
 - c. stirring the reaction mixture at ambient temperature for 30 minutes to 2 hours;
 - 20 and
 - d. isolating the Form A of Fexofenadine.
5. A pure Form A of 4-[4- [4- (hydroxydiphenylmethyl) —1- piperidinyl]—1- hydroxybutyl]- α , α - dimethylbenzene acetic acid, according to any one of claims 1 to 3, wherein the purity of Form A is greater than 99.5%
- 25 6. A crystalline Form X of 4-[4-[4-(hydroxydiphenylmethyl)—1-piperidinyl]—1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride (Form X of Fexofenadine Hydrochloride) of formula (1) which is characterized by the following X-ray powder diffraction pattern (d values in \AA): 16.05, 12.98, 8.29, 8.06, 6.25, 5.97, 5.54, 5.41, 4.89, 4.70, 4.55, 4.37, 4.32, 4.15, 4.03, 3.80, 3.67, 3.57, 3.42.
- 30 7. The crystalline Form X of Fexofenadine Hydrochloride according to claim 6, characterized by the following infrared absorption peaks (in cm^{-1}): FT-IR (In KBr): 3370, 2965, 2652, 1717, 1472, 1448, 1250, 1158, 1100, 1068, 995, 962, 840, 747, 703, 638, 560.

- 14 -

8. The crystalline Form X of Fexofenadine Hydrochloride according to claim 6 or 7, characterized by the DSC thermogram exhibits a melt endotherm with a peak temperature of about 184-189°C.
9. A process for preparing Form X of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride (Form X of Fexofenadine Hydrochloride), which comprises:
- recrystallizing crude Fexofenadine in a (C₁-C₃) alkanol;
 - azeotropically refluxing Fexofenadine in a non polar organic solvent or organic solvent or a mixture thereof for 15 minutes to 6 hours;
 - stirring the reaction mixture at ambient temperature for 30 min to 2 hours;
 - adjusting the pH, of the reaction mass to 1 to 3 with a solvent containing hydrogen chloride;
 - stirring the reaction mass for 30 minutes to 18 hours at ambient temperature;
 - filtering the solid obtained followed by drying at 60-100°C;
 - suspending the solid obtained in step (f) in an alkyl acetate and heating the reaction mixture to reflux for 30 minutes to 6 hours;
 - stirring the reaction mixture at ambient temperature for 20 minutes to 2 hours; and
 - isolating the anhydrous crystalline Form X of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride.
10. A process for preparing Form X of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α -dimethylbenzene acetic acid hydrochloride (Form X of Fexofenadine Hydrochloride), which comprises:
- recrystallizing crude Fexofenadine in a (C₁-C₃) alkanol;
 - azeotropically refluxing Fexofenadine in a non polar organic solvent, organic solvent or a mixture thereof for 15 minutes to 6 hours;
 - stirring the reaction mixture at ambient temperature for 30 min to 2 hours;
 - isolating Fexofenadine Form A;
 - suspending isolated Form A of Fexofenadine in a non polar organic solvent;
 - adjusting the pH, of the reaction mass to 1 to 3 with a solvent containing hydrogen chloride;

- 15 -

g. stirring the reaction mass for 30 minutes to 18 hours at ambient temperature;
h. filtering the solid obtained followed by drying at 60-100°C or by drying at 110-16 under reduced pressure;

i. suspending the solid obtained in step (h) in an alkyl acetate and heating the
5 reaction mixture to reflux for 30 minutes-6 hours;

j. stirring the reaction mixture at ambient temperature for 20 minutes to 2 hours;
and

k. isolating the anhydrous crystalline Form X of 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α - dimethylbenzene acetic
10 acid hydrochloride, by conventional methods.

11. A process for preparing Form X of Fexofenadine Hydrochloride, which comprises:

- a) recrystallizing crude Fexofenadine in (C₁-C₃) alkanol;
b) azeotropically refluxing Fexofenadine in a non polar organic solvent for 3-4
15 hours;
c) optionally isolating the Fexofenadine Form A obtained in step b) by conventional methods accompanied by drying at below 100°C;
d) suspending the Fexofenadine Form A obtained in step c) or adding to the reaction mixture of step b), a mixture of a nonpolar organic solvent or an organic solvent
20 and isopropanol;
e) adjusting the pH of the solution of step e) to 1 to 3 with a solvent containing hydrogen chloride;
f) filtering the solution obtained in step e) to remove particulate matter;
g) seeding the solution of step f) with several crystals of crystalline Form X 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α - dimethylbenzene
25 acetic acid hydrochloride and stirring the reaction mass at ambient temperature to separate the solid;
i) filtering the solid obtained in step h) followed by washing with a nonpolar organic solvent, organic solvent or hydrocarbon solvent; and
30 j) drying the crystalline Form X 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α , α - dimethylbenzene acetic acid hydrochloride.
12. The process as claimed in any one of claims 4 or 9 to 11, wherein the non polar


- 16 -

organic solvent is selected from toluene or xylene.

13. The process as claimed in any of claims 4 or 9 to 12, wherein the (C₁-C₃) alkanol is methanol, ethanol or propanol.
14. The process as claimed in any one of claims 4 or 9 to 13 wherein the nonpolar
5 organic solvent is a (C₆-C₉) alkyl.
15. The process as claimed in any one of claims 4 or 9 to 14, wherein the nonpolar organic solvent is n-hexane, hexane, octane, nonane or cyclohexane.
16. The process as claimed in any one of claims 4 or 9 to 15, wherein the organic solvent is selected from (C₁-C₄) alkyl acetate.
- 10 17. The process according to any one of claims 4 or 9 to 16, wherein the organic solvent is ethyl acetate.
18. The process as claimed in claim 9 step (d), claim 10 step (f) or claim 11 step (e) wherein the solvent containing hydrogen chloride is selected from methanol, ethanol, isopropanol or t-butanol.
- 15 19. The process as claimed in claim 11 wherein the hydrocarbon solvent is selected from hexane or cyclohexane.

1/10

FIG. 1A



SUBSTITUTE SHEET (RULE 26)

2/10

FIG. 1B

Peak Search

Peak No.	2Theta	FWHM	d-value	Intensity	I/I ₀
1	3.820	0.212	23.1110	1032	51
2	7.680	0.235	11.5018	886	44
3	10.660	0.235	8.2922	1614	79
4	12.060	0.400	7.3326	362	18
5	12.580	0.235	7.0306	579	28
6	13.260	0.212	6.6716	982	48
7	13.720	0.118	6.4489	331	16
8	14.360	0.188	6.1629	1016	50
9	14.680	0.235	6.0293	487	24
10	15.400	0.259	5.7490	465	23
11	16.300	0.212	5.4335	1525	75
12	16.620	0.188	5.3296	1064	52
13	17.480	0.235	5.0693	2036	100
14	18.880	0.212	4.6964	550	27
15	19.160	0.376	4.6284	649	32
16	19.960	0.235	4.4447	1334	66
17	20.360	0.235	4.3582	321	16
18	21.120	0.259	4.2031	1057	52
19	21.380	0.165	4.1526	1117	55
20	21.800	0.212	4.0735	770	38

3/10


FIG. 1C

Peak Search

Peak No.	2Theta	FWHM	d-value	Intensity	I/Io
21	22.420	0.141	3.9622	242	12
22	22.640	0.118	3.9242	201	10
23	23.180	0.282	3.8340	281	14
24	24.020	0.259	3.7018	351	17
25	24.680	0.165	3.6043	151	7
26	25.060	0.188	3.5505	432	21
27	25.900	0.188	3.4372	402	20
28	27.160	0.165	3.2805	315	15
29	27.600	0.212	3.2292	84	4
30	28.320	0.118	3.1488	263	13
31	28.540	0.259	3.1250	353	17
32	29.040	0.235	3.0723	181	9
33	29.480	0.118	3.0274	83	4
34	29.720	0.259	3.0035	133	7
35	30.700	0.188	2.9099	162	8
36	31.160	0.141	2.8679	104	5
37	33.660	0.141	2.6604	105	5
38	42.600	0.141	2.1205	111	5
39	44.680	0.141	2.0265	109	5
40	44.820	0.118	2.0205	76	4

4/10


FIG. 2



SUBSTITUTE SHEET (RULE 26)


5/10

FIG. 3



6/10

FIG. 4A



SUBSTITUTE SHEET (RULE 26)

7/10

FIG. 4B**Peak Search**

Peak No.	2Theta	FWHM	d-value	Intensity	I/I ₀
1	5.000	0.118	17.6591	112	7
2	5.500	0.165	16.0548	1255	78
3	6.380	0.118	13.8422	128	8
4	6.800	0.165	12.9882	1051	65
5	10.660	0.165	8.2922	1001	62
6	10.960	0.165	8.0659	444	27
7	13.600	0.188	6.5055	307	19
8	14.140	0.165	6.2583	751	46
9	14.820	0.188	5.9726	464	29
10	15.060	0.141	5.8780	275	17
11	15.440	0.165	5.7342	215	13
12	15.980	0.212	5.5416	1616	100
13	16.360	0.165	5.4137	609	30
14	18.120	0.188	4.8916	1116	69
15	18.840	0.329	4.7063	1573	97
16	19.480	0.188	4.5531	1481	92
17	20.300	0.118	4.3710	369	23
18	20.540	0.259	4.3205	535	33
19	21.360	0.259	4.1564	363	22
20	22.000	0.212	4.0369	938	58
21	22.660	0.212	3.9208	92	6
22	23.380	0.235	3.8017	696	43
23	23.660	0.188	3.7573	256	16
24	24.180	0.212	3.6777	555	34
25	24.880	0.212	3.5758	535	33

8/10


FIG. 4C

Peak Search


Peak No.	2Theta	FWHM	d-value	Intensity	I/Io
26	25.280	0.165	3.5201	159	10
27	26.000	0.376	3.4242	571	35
28	26.520	0.141	3.3582	80	5
29	26.780	0.118	3.3262	80	5
30	27.580	0.259	3.2315	166	10
31	28.120	0.235	3.1707	178	11
32	28.540	0.165	3.1250	186	11
33	29.320	0.188	3.0436	199	12
34	30.680	0.118	2.9117	79	5
35	30.840	0.118	2.8970	91	6
36	31.420	0.235	2.8448	182	11
37	31.800	0.165	2.8117	142	9
38	32.300	0.212	2.7693	95	6
39	32.980	0.259	2.7137	157	10
40	35.840	0.235	2.5034	98	6
41	37.080	0.165	2.4225	91	6
42	39.900	0.212	2.2576	95	6
43	41.060	0.259	2.1964	85	5
44	41.460	0.118	2.1762	78	5

01/6

FIG. 5



10/10

FIG. 6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102777 A3

- (51) International Patent Classification⁷: **C07D 211/22**
- (21) International Application Number: **PCT/US01/23994**
- (22) International Filing Date: **31 July 2001 (31.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
484/MAS/2001 **18 June 2001 (18.06.2001)** **IN.**
- (71) Applicant (for all designated States except GD, US): **DR. REDDY'S LABORATORIES LTD.** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).
- (71) Applicant (for GD only): **CORD, Janet, I.** [US/US]; 26 West 61st Street, New York, NY 10023 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **REDDY, M., Satyanarayana** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016, A.P. (IN). **RAJAN, S., Thirumalai** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN). **RAO, U., V., Bhaskara** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).
- (74) Agent: **CORD, Janet, I.**; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- (88) Date of publication of the international search report:
27 February 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-5G(A), 5G(A)-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE**

(57) Abstract: The present invention is related to novel polymorph of Fexofenadine and Fexofenadine hydrochloride of formula 1 and process of preparation thereof. The present invention is also directed to provide pure novel polymorphs of Fexofenadine and its hydrochloride by a simple process which is cost effective, commercially viable and environment friendly.

WO 02/102777 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23994

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D211/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 23213 A (ALBANY MOLECULAR RES INC) 3 July 1997 (1997-07-03) example 14	1-3
A	US 4 254 129 A (CARR ALBERT A ET AL) 3 March 1981 (1981-03-03) cited in the application example 3	1,6
E	WO 02 10115 A (MILLA FEDERICO JUNQUERA ;TEXCONTOR ETS (LI)) 7 February 2002 (2002-02-07) example 11	1-3

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 July 2002

Date of mailing of the international search report

26/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 01/23994

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9723213	A	03-07-1997	US 6153754 A	28-11-2000
			AU 723231 B2	24-08-2000
			AU 1337197 A	17-07-1997
			BR 9612216 A	28-12-1999
			CA 2240927 A1	03-07-1997
			EP 0868182 A1	07-10-1998
			JP 2000502348 T	29-02-2000
			NO 982770 A	16-06-1998
			NZ 326085 A	27-04-2001
			WO 9723213 A1	03-07-1997
US 4254129	A	03-03-1981	AT 376208 B	25-10-1984
			AT 144880 A	15-03-1984
			AU 531146 B2	11-08-1983
			AU 5501680 A	16-10-1980
			BE 882703 A1	31-07-1980
			CA 1123438 A1	11-05-1982
			CH 643245 A5	30-05-1984
			DE 3007498 A1	23-10-1980
			DK 132980 A ,B,	11-10-1980
			ES 489934 D0	16-03-1981
			ES 8103735 A1	16-06-1981
			FR 2453854 A1	07-11-1980
			GB 2048258 A ,B	10-12-1980
			IE 49672 B1	27-11-1985
			IL 59158 A	30-04-1984
			IT 1143960 B	29-10-1986
			JP 1032823 B	10-07-1989
			JP 1555761 C	23-04-1990
			JP 55141469 A	05-11-1980
			NL 8000754 A ,B,	14-10-1980
			NO 801014 A ,B,	13-10-1980
			NZ 192653 A	16-03-1982
			PH 17023 A	11-05-1984
			SE 448726 B	16-03-1987
			SE 8002634 A	11-10-1980
			US 4285957 A	25-08-1981
			ZA 8000332 A	28-01-1981
WO 0210115	A	07-02-2002	AU 6938801 A	13-02-2002
			WO 0210115 A1	07-02-2002

THIS PAGE BLANK (USPTO)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102777 A3

(51) International Patent Classification⁷: C07D 211/22

(21) International Application Number: PCT/US01/23994

(22) International Filing Date: 31 July 2001 (31.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
484/MAS/2001 18 June 2001 (18.06.2001) IN

(71) Applicant (for all designated States except GD, US): **DR. REDDY'S LABORATORIES LTD.** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).

(71) Applicant (for GD only): **CORD, Janet, I.** [US/US]; 26 West 61st Street, New York, NY 10023 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REDDY, M., Satyanarayana** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016, A.P. (IN). **RAJAN, S., Thirumalai** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN). **RAO, U., V., Bhaskara** [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500016, A.P. (IN).

(74) Agent: **CORD, Janet, I.**; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
27 February 2003

(48) Date of publication of this corrected version:
30 October 2003

(15) Information about Correction:
see PCT Gazette No. 44/2003 of 30 October 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]- α , α -DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE

(57) Abstract: The present invention is related to novel polymorph of Fexofenadine and Fexofenadine hydrochloride of formula 1 and process of preparation thereof. The present invention is also directed to provide pure novel polymorphs of Fexofenadine and its hydrochloride by a simple process which is cost effective, commercially viable and environment friendly.

WO 02/102777 A3

THIS PAGE BLANK (USPTO)